Research map: Changing Treatment Landscape of Hepatocellular Carcinoma: A Real-World Retrospective Analysis of Treatment Algorithms and Outcomes of Patients over 10 Years

Back to the article

Papers in this map

  1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries · Freddie Bray · 2024 · 26051 citations · Cited by this paper
  2. Cardiotoxicity Profiles of Osimertinib Compared with Other EGFR Tyrosine Kinase Inhibitors: A Real-World Comparative Incidence Analysis · 2025 · Related
  3. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma · Richard S. Finn · 2020 · 7562 citations · Cited by this paper
  4. Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer · 2026 · Related
  5. Hepatocellular carcinoma · Josep Maria Llovet · 2021 · 6739 citations · Cited by this paper
  6. MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies · 2025 · Related
  7. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update · María Reig · 2021 · 4352 citations · Cited by this paper
  8. Targeting DNA Damage Repair Pathways Beyond PARP Inhibition · 2025 · Related
  9. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma · Ghassan K. Abou‐Alfa · 2022 · 1540 citations · Cited by this paper
  10. Real-World Treatment Patterns in Advanced Cutaneous Melanoma in the USA · 2026 · Related
  11. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study · Shukui Qin · 2023 · 732 citations · Cited by this paper
  12. Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges · 2026 · Related
  13. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. · Ghassan K. Abou‐Alfa · 2022 · 406 citations · Cited by this paper
  14. Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer · 2026 · Related
  15. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). · Richard S. Finn · 2021 · 321 citations · Cited by this paper
  16. Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma? · 2026 · Related
  17. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study · Masatoshi Kudo · 2025 · 319 citations · Cited by this paper
  18. Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study) · 2026 · Related
  19. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up · Arndt Vogel · 2025 · 265 citations · Cited by this paper
  20. Hepatitis C · Marianne Martinello · 2023 · 180 citations · Cited by this paper
  21. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. · Riccardo Antonio Lencioni · 2024 · 159 citations · Cited by this paper
  22. The evolutionary scenario of hepatocellular carcinoma in Italy: an update · Laura Bucci · 2017 · 83 citations · Cited by this paper
  23. Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study · Masatoshi Kudo · 2023 · 64 citations · Cited by this paper
  24. The Current Landscape of Clinical Trials for Systemic Treatment of HCC · Friedrich Wilhelm Foerster · 2021 · 61 citations · Cited by this paper
  25. LBA2 TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC) · Jiahong Dong · 2025 · 44 citations · Cited by this paper
  26. Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death · Giuseppe Cabibbo · 2024 · 36 citations · Cited by this paper
  27. MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis · Carole Vitellius · 2024 · 30 citations · Cited by this paper
  28. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment · Filippo Pelizzaro · 2022 · 20 citations · Cited by this paper
  29. Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma · Masatoshi Kudo · 2024 · 20 citations · Cited by this paper
  30. Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review · Arndt Vogel · 2023 · 17 citations · Cited by this paper
  31. Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study · Yoon Jun Kim · 2024 · 15 citations · Cited by this paper
  32. Systemic Treatment in Intermediate Stage (Barcelona Clinic Liver Cancer-B) Hepatocellular Carcinoma · Dimitrios S. Karagiannakis · 2023 · 11 citations · Cited by this paper
  33. Immune Checkpoint Inhibitor in Hepatocellular Carcinoma: Response Rates, Adverse Events, and Predictors of Response · Shekhar Swaroop · 2025 · 4 citations · Cited by this paper
  34. A new standard for HCC: The high stakes of TACE-immunotherapy combinations · Antonio D’Alessio · 2025 · 4 citations · Cited by this paper
  35. Untitled · Cited by this paper

Source: OpenAlex (CC0)